Evidence map›Paper›PMID 23041058›Full record

ReviewPharmacology & therapeutics2013

Dietary phytochemicals and cancer prevention: Nrf2 signaling, epigenetics, and cell death mechanisms in blocking cancer initiation and progression.

Jong Hun Lee, Tin Oo Khor, Limin Shu, Zheng-Yuan Su, Francisco Fuentes, Ah-Ng Tony Kong

Abstract readReview
In one paragraph

Review in Pharmacology & therapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed
9.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 243 citations in OpenAlex.

  1. Review
  2. International journal of molecular sciences · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Potential Harm of IQOS Smoke to Rat Liver.International journal of molecular sciences · 2023
    Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Jong Hun LeeCenter for Cancer Prevention Research, Department of Pharmaceutics, Ernest-Mario School of Pharmacy, Rutgers, the State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA.
Tin Oo Khor
Limin Shu
Zheng-Yuan Su
Francisco Fuentes
Ah-Ng Tony Kong
Rutgers, The State University of New Jersey · USArturo Prat University · CL

Funding

Translational Research Support CoreP30ES005022 · NIEHS · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI ROBERT John LAUMBACH · 1988 to 2026
$47.4M
REGULATION OF PHASE 2 GENES BY ISOTHIOCYANATESR01CA073674 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI KONG, AH-NG TONY · 1999 to 2012
$3.6M
Induction of Phase 2 Genes by Chemopreventive Agent BHAR01CA094828 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI KONG, AH-NG TONY · 2001 to 2011
$2.9M
Epigenetic modifications by dietary PEITC in prostate cancerR01CA118947 · NCI · RUTGERS, THE STATE UNIV OF N.J. · PI KONG, AH-NG TONY · 2006 to 2015
$2.8M
Curcuma Longa: epigenetic effects in prostate and colon cancerR01AT007065 · NCCIH · RUTGERS, THE STATE UNIV OF N.J. · PI KONG, AH-NG TONY · 2012 to 2016
$2.3M
Prostate cancer prevention by tocopherolsR01CA152826 · NCI · RUTGERS, THE STATE UNIV OF N.J. · PI KONG, AH-NG TONY · 2011 to 2015
$1.6M
NCCIH NIH HHS R01 AT007065NCCIH NIH HHS R01AT007065NCI NIH HHS R01 CA073674NCI NIH HHS R01 CA094828NCI NIH HHS R01 CA118947NCI NIH HHS R01-CA118947NCI NIH HHS R01 CA152826NCI NIH HHS R01-CA152826NCI NIH HHS R01-CA73674NCI NIH HHS R01-CA94828NIEHS NIH HHS P30 ES005022
6 · The paper itself

Abstract

Reactive metabolites from carcinogens and oxidative stress can drive genetic mutations, genomic instability, neoplastic transformation, and ultimately carcinogenesis. Numerous dietary phytochemicals in vegetables/fruits have been shown to possess cancer chemopreventive effects in both preclinical animal models and human epidemiological studies. These phytochemicals could prevent the initiation of carcinogenesis via either direct scavenging of reactive oxygen species/reactive nitrogen species (ROS/RNS) or, more importantly, the induction of cellular defense detoxifying/antioxidant enzymes. These defense enzymes mediated by Nrf2-antioxidative stress and anti-inflammatory signaling pathways can contribute to cellular protection against ROS/RNS and reactive metabolites of carcinogens. In addition, these compounds would kill initiated/transformed cancer cells in vitro and in in vivo xenografts via diverse anti-cancer mechanisms. These mechanisms include the activation of signaling kinases (e.g., JNK), caspases and the mitochondria damage/cytochrome c pathways. Phytochemicals may also have anti-cancer effects by inhibiting the IKK/NF-κB pathway, inhibiting STAT3, and causing cell cycle arrest. In addition, other mechanisms may include epigenetic alterations (e.g., inhibition of HDACs, miRNAs, and the modification of the CpG methylation of cancer-related genes). In this review, we will discuss: the current advances in the study of Nrf2 signaling; Nrf2-deficient tumor mouse models; the epigenetic control of Nrf2 in tumorigenesis and chemoprevention; Nrf2-mediated cancer chemoprevention by naturally occurring dietary phytochemicals; and the mutation or hyper-expression of the Nrf2-Keap1 signaling pathway in advanced tumor cells. The future development of dietary phytochemicals for chemoprevention must integrate in vitro signaling mechanisms, relevant biomarkers of human diseases, and combinations of different phytochemicals and/or non-toxic therapeutic drugs, including NSAIDs.

Indexed as

DietEpigenesis, GeneticAnimalsAnticarcinogenic AgentsApoptosisDisease ProgressionHumansNeoplasmsNF-E2-Related Factor 2Oxidative StressPhytotherapySignal TransductionAnticarcinogenic AgentsNF-E2-Related Factor 2

Identifiers

PMID23041058
PMCPMC3694988
OpenAlexW2067656886

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.